12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Peramivir: Preliminary Phase III data

Top-line data from the open-label, international Phase III BCX1812-303 trial in 127 evaluable hospitalized patients with confirmed influenza showed that a once-daily infusion of 600 mg IV peramivir for 5 days led to similar reductions in influenza virus titer as measured by log10 TCID50, the primary endpoint, compared to a twice-daily infusion of 300 mg for...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >